Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Equal Weight Standard Chartered (STAN) by Barclays
- Avoid Celadon Pharmaceuticals (CEL) by Tom Winnifrith in ShareProphets
- Buy Diploma (DPLM) by Stephen Wright in The Motley Fool
- Avoid Judges Scientific (JDG) by Steve Moore in ShareProphets
- Buy British American Tobacco (BATS) by Simon Watkins in The Motley Fool
- Buy BP (BP.) by Harvey Jones in The Motley Fool
- Buy Legal & General Group (LGEN) by Harvey Jones in The Motley Fool
- Neutral Smith (DS) (SMDS) by Davy
- Buy Genuit Group (GEN) by Jefferies
- Neutral Genuit Group (GEN) by JP Morgan
- Hold Ashmore Group (ASHM) by Deutsche Bank
- Buy IQE (IQE) by Deutsche Bank
- Hold FDM Group (Holdings) (FDM) by Deutsche Bank
- Buy Vodafone Group (VOD) by Simon Watkins in The Motley Fool
- Sector Perform Tesco (TSCO) by RBC Capital
- Outperform Sainsbury (J) (SBRY) by RBC Capital
- Hold Nichols (NICL) by Russ Mould in The Telegraph - Questor
- Hold DCC (CDI) (DCC) by Russ Mould in The Telegraph - Questor
- Sell Ricardo (RCDO) by Russ Mould in The Telegraph - Questor
- Neutral Young & Co's Brewery 'A' Shares (YNGA) by JP Morgan
Theracryf (TCF) Share Price
NOTE: This is based on 0 open tips for Theracryf (TCF)
| Latest Bid : 0.50p | Latest Ask : 0.55p |
| High Today : 0.55p | Low Today : 0.49p |
| This Years High : 1.85p | This Years Low : 0.49p |
| Volume : 280,522 | MKT Cap : £2.35M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Theracryf (TCF) Overview
TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf's strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company's clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos' neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.Theracryf (TCF) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.50p | Latest Ask : 0.55p |
| High Today : 0.55p | Low Today : 0.49p |
| This Years High : 1.85p | This Years Low : 0.49p |
| Volume : 280,522 | MKT Cap : £2.35M |
Theracryf Overview
TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf's strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company's clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos' neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.